Oyster Therapeutics
United Kingdom · Biotech
Oyster Therapeutics develops protein-degrader medicines for neurodegenerative diseases.
Product
Oyster Therapeutics develops medicines designed to remove disease-causing proteins through the cell’s own clearance machinery. Its initial focus is neurodegenerative disease, including Alzheimer’s disease.
The company’s SELFTAC platform uses smaller molecular components that can cross biological barriers before assembling into an active protein degrader. The approach is designed to improve oral delivery and access to targets in the central nervous system.
Based in the UK, Oyster is developing a programme targeting tau protein and works with Massachusetts General Hospital on research supporting that effort.
Funding history
1 round · 1 with disclosed amounts| Announced | Round | Amount | Investors |
|---|---|---|---|
| Series A-2 | $60M | 4BIO Capital — LeadActium Group — ParticipantCE-Ventures — ParticipantEli Lilly and Company — ParticipantMass General Brigham Ventures — ParticipantMission BioCapital — ParticipantOxford Science Enterprises — ParticipantSyncona — ParticipantTOHO Ventures — Participant |
Investors
4BIO CapitalLed Series A-2Actium GroupJoined Series A-2CE-VenturesJoined Series A-2Eli Lilly and CompanyJoined Series A-2Mass General Brigham VenturesJoined Series A-2Mission BioCapitalJoined Series A-2Oxford Science EnterprisesJoined Series A-2SynconaJoined Series A-2TOHO VenturesJoined Series A-2Coverage
Nov 10, 2026Oyster Therapeutics · Series A-2Similar companies
SSSunlit SeedlingsSunlit Seedlings measures biodiversity and microbial activity to help organisations assess and redesign ecosystems.Undisclosed · Corporate investment
BiomatterBiomatter designs custom enzymes for pharmaceutical, diagnostic, agricultural and industrial applications.$18M · Series A
OOOrakl OncologyCombines patient-derived tumour organoids, clinical data and AI to help pharmaceutical companies develop cancer treatments.$34M · Series A